The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. It features a continuously-updated map tracking the status of abortion bans across the United States, as well as briefs on topics such as medication abortion, insurance coverage, ballot measures, legal developments, and racial and ethnic disparities. It also offers a jumping off point to the latest national and state-specific abortion policies and statistics. Visit the Dashboard →
The Supreme Court will be hearing oral arguments for the case FDA v. Alliance for Hippocratic Medicine. This brief explains the issues at stake before the court and their implications for the drug regulatory process and medication abortion access throughout the country.
This issue brief details the Alliance of Hippocratic Medicine challenge to the FDA's approval of the abortion pill, mifepristone. It provides context for the challenge, as well as what some of the possible rulings in the case could mean for access to medication abortion.
This brief provides background on the Comstock Act, reviews how it has been interpreted by the Biden Administration’s DOJ, and considers how it could be enforced by an administration that is hostile toward abortion to severely restrict the distribution of drugs and supplies used for abortion, with implications for abortion access in all states across the country.
This issue brief presents an overview of the legal challenges presented in state courts since the Dobbs ruling in June 2022 and highlights some of the novel strategies that are being used to defend access to abortion in states that have enacted abortion bans.
Despite for calls from Republican leaders and anti-abortion organizations for the FDA to act quickly, the Louisiana district court has given the FDA until October 7, 2026, one month before the midterms, to file a report with the status of its review and any updated timeframe for completion. In the meantime, clinicians may continue to mail mifepristone to pregnant patients seeking abortions regardless of where they live.
In addition to ongoing litigation, last September the Trump administration FDA, after requests from anti-abortion organizations and state attorneys general, initiated an internal review of mifepristone’s safety. This adds uncertainty as the agency could revise dispensing rules independently of the courts. With the FDA commissioner’s resignation this week and no permanent leader in place, the timeline for completing the review remains unclear.
This brief explains why individuals may seek abortions later in pregnancy, how often these procedures occur, and the various laws which regulate access to abortions later in pregnancy across the country.
This issue brief examines the varying exceptions (for life, health, rape/incest, and fatal fetal anomalies) in state abortion bans and restrictions and the complications that arise when pregnant people attempt to access abortion care under these exceptions.
On April 24, 2024, the Supreme Court will hear the second case this term involving access to abortion: Idaho v. United States. At stake in this case is whether the Emergency Medical Treatment and Active Labor Act, a federal law requiring hospitals to provide stabilizing treatment to patients who present to their emergency rooms, preempts state abortion laws and requires hospitals that accept Medicare to provide abortion care when it is necessary to stabilize a…
While former President Trump has stated that overturning Roe v. Wade turned the decision of abortion back to states and “the people are now deciding,” it is a complicated political and legal road
© 2026 KFF